The Clinical Core is critical to the function of the Indiana Alzheimer Disease Center. Its role is to recruit, clinically characterize and longitudinally follow patients with MCI, AD, non-AD and mixed dementia and healthy controls. A major emphasis is to identify and clinically characterize families with AD and new genetically distinct non-AD dementias with emphasis on identifying patients in the earliest stages of illness. These patients will be further characterized by the Neuropathology Core. In conjunction with the Neuropathology Core, the Clinical Core will obtain and bank biology materials (DNA, plasma and CSF) from participating subjects to support studies pertaining to dementias. Patients from the Clinical Core will be offered as appropriate participation in ADNI, LOAD, investigational drug trials and other local and multicenter research studies. We will continue to support the NCRAD. We will continue our educational efforts in the general elderly as well as African American communities to communicate and facilitate autopsy. After autopsy, clinical-genetic-neuropathological correlation will increase the understanding of AD and non-AD dementias and support further investigations of biochemical abnormalities and/or underlying disease mechanisms.

Public Health Relevance

It is estimated that as many as 5 million Americans have AD. The Indiana Alzheimer Disease Center provides an environment and resources directed towards fostering and coordinating research and educational activities on AD and other dementing illnesses.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG010133-24
Application #
8690693
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
24
Fiscal Year
2014
Total Cost
Indirect Cost
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Chapman, Kimberly R; Bing-Canar, Hanaan; Alosco, Michael L et al. (2016) Mini Mental State Examination and Logical Memory scores for entry into Alzheimer's disease trials. Alzheimers Res Ther 8:9
Kovacs, Gabor G; Ferrer, Isidro; Grinberg, Lea T et al. (2016) Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol 131:87-102
Nho, Kwangsik; Saykin, Andrew J (2016) Reply. Ann Neurol 79:335
Lahiri, Debomoy K; Maloney, Bryan; Bayon, Baindu L et al. (2016) Transgenerational latent early-life associated regulation unites environment and genetics across generations. Epigenomics 8:373-87
Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-20
Green, Colin; Zhang, Shenqiu (2016) Predicting the progression of Alzheimer's disease dementia: A multidomain health policy model. Alzheimers Dement 12:776-85
Nudelman, Kelly N H; McDonald, Brenna C; Wang, Yang et al. (2016) Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy. J Clin Oncol 34:677-83
Ringman, John M; Monsell, Sarah; Ng, Denise W et al. (2016) Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol 75:284-90
Li, Wei; Risacher, Shannon L; McAllister, Thomas W et al. (2016) Erratum to: Traumatic brain injury and age at onset of cognitive impairment in older adults. J Neurol 263:1286
Jun, G; Ibrahim-Verbaas, C A; Vronskaya, M et al. (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21:108-17

Showing the most recent 10 out of 451 publications